Tirzepatide is a dual-receptor agonist that targets both GLP-1 and GIP (Mounjaro and Zepbound class)
Click to view more FOXO4 D-Retro-Inverso peptide , also known as FOXO4 DRI peptide was first reported in 'Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging' by Baar et al
Dr Noluthando Nematswerani, chief clinical officer at Discovery Health, said the GLP-1 agonists (Ozempic, Trulicity, Victoza, Mounjaro, Soliqua) registered by SAHPRA for the treatment of type 2 diabetes are covered under certain conditions
Lets dive into each one in more detail and discover what you need to know about B vitamins and their role in human health
Thats because estrogen and progesterone levels shift dramatically during the menstrual cycle
Make exercise a routine, not a chore